SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (NASDAQ: PCRX) securities between August 2, 2023 and August 8, 2024. Pacira is an American pharmaceutical company committed to developing and providing non-opioid pan management and regenerative health solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 35 ...

Lawsuit Allegations - A shareholder class action lawsuit has been filed against Pacira BioSciences, Inc alleging that the company created a false impression regarding the sufficiency of patent protections on Exparel, impacting its marketing, production, and sales [1] - The lawsuit claims that Pacira was aware that the '495 patent was not as protective as publicly stated by the company [1] Legal Action Details - Shareholders who purchased Pacira shares between August 2, 2023, and August 8, 2024, and suffered significant losses are encouraged to contact Corey D Holzer, Esq for legal rights discussion [2] - The deadline to request the court to be appointed lead plaintiff in the case is March 14, 2025 [3] Law Firm Information - Holzer & Holzer, LLC, a top-rated securities litigation law firm, specializes in representing shareholders and investors in litigation, including class action and derivative cases [3] - Since its founding in 2000, the firm has recovered hundreds of millions of dollars for shareholders affected by fraud and corporate misconduct [3]

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Pacira BioSciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) between August 2, 2023 to August 8, 2024, both dates inclusive. You are hereby notified that the class action lawsuit Leandro Alvarez v. Pacira BioSciences, Inc., et al. (Case No. 2:25-cv-00322) has been commenced in the United States District Court for th ...

Shares of Pacira BioSciences (PCRX) gained 11.1% on Friday after the company shared better-than-expected preliminary fourth-quarter 2024 sales figures for its marketed products.Additionally, the company unveiled a five-year growth strategy aimed at accelerating its transformation into an innovative biopharmaceutical company and establishing itself as a leader in musculoskeletal pain and related areas. This has also likely contributed to the stock price rally.PCRX’s Preliminary Q4 2024 ResultsExparel’s net p ...

Earnings and Revenue Expectations - The specialty drugmaker is expected to post quarterly earnings of $0 83 per share, representing a year-over-year change of -6 7% [1] - Revenues are expected to be $178 98 million, down 1 3% from the year-ago quarter [1] - Empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements [1] Pacira (PCRX) Stock Performance and Estimates - The consensus EPS estimate for Pacira has been revised 0 6% lower over the last 30 days [2] - Pacira shares ended the last trading session 11 1% higher at $20 64, with a higher-than-average trading volume [3] - The stock had previously experienced a 6 2% loss over the past four weeks [3] - The sudden rise in stock price followed better-than-expected preliminary fourth-quarter 2024 sales figures and the unveiling of a five-year growth strategy [4] Industry and Peer Comparison - Pacira is a member of the Zacks Medical - Biomedical and Genetics industry [2] - Travere Therapeutics (TVTX), another stock in the same industry, finished the last trading session 4 8% lower at $18 09 but has returned 6 1% over the past month [2] - Travere's consensus EPS estimate for the upcoming report has changed -7 6% over the past month to -$0 61, representing a year-over-year change of +47 4% [5] - Travere currently holds a Zacks Rank of 2 (Buy) [5]

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization -- Company also reports preliminary unaudited 2024 revenue of $701.0 million -- Parsippany, NJ., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth-oriented plan to accelerate ...

Company also reports preliminary unaudited 2024 revenue of $701.0 millionPARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth-oriented plan to accelerate its ongoing transition into an innovative biopharmaceutical organization and become a therapeutic area leader in musculoskeletal pain and adjacencies. In addi ...

Pacira BioSciences (PCRX) announced that the FDA has cleared its application to market a new Smart Tip for the iovera system designed to access the medial branch nerves to manage chronic low back pain. Please note that this hand-held medical device was added to Pacira’s portfolio following the acquisition of MyoScience.The iovera system is a groundbreaking, FDA-approved, drug-free treatment that alleviates pain through cryoneurolysis. This technique uses targeted cold therapy to temporarily disrupt a nerve' ...

PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain. The ioveraº system is an innovative, FDA-cleared, drug-free treatment that relieves pain via cryoneurolysis—a ...

PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain. The ioveraº system is an innovative, FDA-cleared, drug-free treatment that relieves pain via cryoneurolysis—a ...